Literature DB >> 20028567

Cancer risk in MLH1, MSH2 and MSH6 mutation carriers; different risk profiles may influence clinical management.

Dewkoemar Ramsoekh1, Anja Wagner, Monique E van Leerdam, Dennis Dooijes, Carli Mj Tops, Ewout W Steyerberg, Ernst J Kuipers.   

Abstract

BACKGROUND: Lynch syndrome (LS) is associated with a high risk for colorectal cancer (CRC) and extracolonic malignancies, such as endometrial carcinoma (EC). The risk is dependent of the affected mismatch repair gene. The aim of the present study was to calculate the cumulative risk of LS related cancers in proven MLH1, MSH2 and MSH6 mutation carriers.
METHODS: The studypopulation consisted out of 67 proven LS families. Clinical information including mutation status and tumour diagnosis was collected. Cumulative risks were calculated and compared using Kaplan Meier survival analysis.
RESULTS: MSH6 mutation carriers, both males and females had the lowest risk for developing CRC at age 70 years, 54% and 30% respectively and the age of onset was delayed by 3-5 years in males. With respect to endometrial carcinoma, female MSH6 mutation carriers had the highest risk at age 70 years (61%) compared to MLH1 (25%) and MSH2 (49%). Also, the age of EC onset was delayed by 5-10 years in comparison with MLH1 and MSH2.
CONCLUSIONS: Although the cumulative lifetime risk of LS related cancer is similar, MLH1, MSH2 and MSH6 mutations seem to cause distinguishable cancer risk profiles. Female MSH6 mutation carriers have a lower CRC risk and a higher risk for developing endometrial carcinoma. As a consequence, surveillance colonoscopy starting at age 30 years instead of 20-25 years is more suitable. Also, prophylactic hysterectomy may be more indicated in female MSH6 mutation carriers compared to MLH1 and MSH2 mutation carriers.

Entities:  

Year:  2009        PMID: 20028567      PMCID: PMC2804564          DOI: 10.1186/1897-4287-7-17

Source DB:  PubMed          Journal:  Hered Cancer Clin Pract        ISSN: 1731-2302            Impact factor:   2.857


  31 in total

1.  Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset.

Authors:  Heather Hampel; Julie A Stephens; Eero Pukkala; Risto Sankila; Lauri A Aaltonen; Jukka-Pekka Mecklin; Albert de la Chapelle
Journal:  Gastroenterology       Date:  2005-08       Impact factor: 22.682

2.  Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment.

Authors:  F Quehenberger; H F A Vasen; H C van Houwelingen
Journal:  J Med Genet       Date:  2005-06       Impact factor: 6.318

3.  Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome.

Authors:  Kathleen M Schmeler; Henry T Lynch; Lee-may Chen; Mark F Munsell; Pamela T Soliman; Mary Beth Clark; Molly S Daniels; Kristin G White; Stephanie G Boyd-Rogers; Peggy G Conrad; Kathleen Y Yang; Mary M Rubin; Charlotte C Sun; Brian M Slomovitz; David M Gershenson; Karen H Lu
Journal:  N Engl J Med       Date:  2006-01-19       Impact factor: 91.245

4.  Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome.

Authors:  Laura Renkonen-Sinisalo; Ralf Bützow; Arto Leminen; Pentti Lehtovirta; Jukka-Pekka Mecklin; Heikki J Järvinen
Journal:  Int J Cancer       Date:  2007-02-15       Impact factor: 7.396

5.  Decrease in mortality in Lynch syndrome families because of surveillance.

Authors:  Andrea E de Jong; Yvonne M C Hendriks; Jan H Kleibeuker; Sybrand Y de Boer; Annemieke Cats; Gerrit Griffioen; Fokko M Nagengast; Frits G Nelis; Matti A Rookus; Hans F A Vasen
Journal:  Gastroenterology       Date:  2006-03       Impact factor: 22.682

6.  Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations.

Authors:  E Barrow; L Robinson; W Alduaij; A Shenton; T Clancy; F Lalloo; J Hill; D G Evans
Journal:  Clin Genet       Date:  2009-02       Impact factor: 4.438

7.  The use of genetic testing in hereditary colorectal cancer syndromes: genetic testing in HNPCC, (A)FAP and MAP.

Authors:  D Ramsoekh; M E van Leerdam; C M J Tops; D Dooijes; E W Steyerberg; E J Kuipers; A Wagner
Journal:  Clin Genet       Date:  2007-10-07       Impact factor: 4.438

8.  Heterozygous mutations in PMS2 cause hereditary nonpolyposis colorectal carcinoma (Lynch syndrome).

Authors:  Yvonne M C Hendriks; Shantie Jagmohan-Changur; Heleen M van der Klift; Hans Morreau; Marjo van Puijenbroek; Carli Tops; Theo van Os; Anja Wagner; Margreet G F M Ausems; Encarna Gomez; Martijn H Breuning; Annette H J T Bröcker-Vriends; Hans F A Vasen; Juul Th Wijnen
Journal:  Gastroenterology       Date:  2006-02       Impact factor: 22.682

9.  Colorectal cancer in HNPCC: cumulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven mutations.

Authors:  E Barrow; W Alduaij; L Robinson; A Shenton; T Clancy; F Lalloo; J Hill; D G Evans
Journal:  Clin Genet       Date:  2008-06-28       Impact factor: 4.438

Review 10.  Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer).

Authors:  H F A Vasen; G Möslein; A Alonso; I Bernstein; L Bertario; I Blanco; J Burn; G Capella; C Engel; I Frayling; W Friedl; F J Hes; S Hodgson; J-P Mecklin; P Møller; F Nagengast; Y Parc; L Renkonen-Sinisalo; J R Sampson; A Stormorken; J Wijnen
Journal:  J Med Genet       Date:  2007-02-27       Impact factor: 6.318

View more
  24 in total

1.  Evaluation of Lynch syndrome modifier genes in 748 MMR mutation carriers.

Authors:  Solene Houlle; Françoise Charbonnier; Estelle Houivet; Julie Tinat; Marie-Pierre Buisine; Olivier Caron; Jacques Benichou; Stéphanie Baert-Desurmont; Thierry Frebourg
Journal:  Eur J Hum Genet       Date:  2011-03-16       Impact factor: 4.246

2.  Current Lynch syndrome tumor screening practices: a survey of genetic counselors.

Authors:  Stephanie A Cohen
Journal:  J Genet Couns       Date:  2013-05-15       Impact factor: 2.537

3.  MSH6 and PMS2 mutation positive Australian Lynch syndrome families: novel mutations, cancer risk and age of diagnosis of colorectal cancer.

Authors:  Bente A Talseth-Palmer; Mary McPhillips; Claire Groombridge; Allan Spigelman; Rodney J Scott
Journal:  Hered Cancer Clin Pract       Date:  2010-05-21       Impact factor: 2.857

4.  Identifying targets of miR-143 using a SILAC-based proteomic approach.

Authors:  Yi Yang; Raghothama Chaerkady; Kumaran Kandasamy; Tai-Chung Huang; Lakshmi Dhevi N Selvan; Sutopa B Dwivedi; Oliver A Kent; Joshua T Mendell; Akhilesh Pandey
Journal:  Mol Biosyst       Date:  2010-06-14

Review 5.  Practical issues related to uterine pathology: staging, frozen section, artifacts, and Lynch syndrome.

Authors:  Robert A Soslow
Journal:  Mod Pathol       Date:  2016-01       Impact factor: 7.842

6.  Quality colonoscopy and risk of interval cancer in Lynch syndrome.

Authors:  J F Haanstra; H F A Vasen; S Sanduleanu; E J van der Wouden; J J Koornstra; J H Kleibeuker; W H de Vos Tot Nederveen Cappel
Journal:  Int J Colorectal Dis       Date:  2013-07-16       Impact factor: 2.571

7.  Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study.

Authors:  Marlies J E Kempers; Roland P Kuiper; Charlotte W Ockeloen; Pierre O Chappuis; Pierre Hutter; Nils Rahner; Hans K Schackert; Verena Steinke; Elke Holinski-Feder; Monika Morak; Matthias Kloor; Reinhard Büttner; Eugene T P Verwiel; J Han van Krieken; Iris D Nagtegaal; Monique Goossens; Rachel S van der Post; Renée C Niessen; Rolf H Sijmons; Irma Kluijt; Frans B L Hogervorst; Edward M Leter; Johan J P Gille; Cora M Aalfs; Egbert J W Redeker; Frederik J Hes; Carli M J Tops; Bernadette P M van Nesselrooij; Marielle E van Gijn; Encarna B Gómez García; Diana M Eccles; David J Bunyan; Sapna Syngal; Elena M Stoffel; Julie O Culver; Melanie R Palomares; Tracy Graham; Lea Velsher; Janos Papp; Edith Oláh; Tsun L Chan; Suet Y Leung; Ad Geurts van Kessel; Lambertus A L M Kiemeney; Nicoline Hoogerbrugge; Marjolijn J L Ligtenberg
Journal:  Lancet Oncol       Date:  2010-12-08       Impact factor: 41.316

8.  Correlation between germline mutations in MMR genes and microsatellite instability in ovarian cancer specimens.

Authors:  Mohammad R Akbari; Shiyu Zhang; Deborah Cragun; Ji-Hyun Lee; Domenico Coppola; John McLaughlin; Harvey A Risch; Barry Rosen; Patricia Shaw; Thomas A Sellers; Joellen Schildkraut; Steven A Narod; Tuya Pal
Journal:  Fam Cancer       Date:  2017-07       Impact factor: 2.375

Review 9.  Cancer risk in Lynch Syndrome.

Authors:  Emma Barrow; James Hill; D Gareth Evans
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

10.  Mismatch repair gene mutation analysis and colonoscopy surveillance in Chinese Lynch syndrome families.

Authors:  Lei Fu; Jian-qiu Sheng; Xiao-ou Li; Peng Jin; Hong Mu; Min Han; Ji-sheng Huang; Zi-qin Sun; Ai-qin Li; Zi-tao Wu; Shi-rong Li
Journal:  Cell Oncol (Dordr)       Date:  2013-05-03       Impact factor: 6.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.